See the latest news and media coverage for KDventures. We track all announcements, press releases, and industry mentions in real time, all in one place.
Life science investment company
kd-ventures.comLast updated
In short: KDventures completed SEK 220 million Rosetta deal and reported improved results amid portfolio progress.
Umecrine Cognition showed no significant improvement in cognition or fatigue for golexanolon in PBC. KDventures adjusts the value of its holding from SEK 226.4 million to SEK 0 million with immediate effect.
The company reports increased profit and positive clinical data from portfolio companies as well as new partnerships.
The net asset value per share decreases to SEK 0.89 after write-downs of Umecrine Cognition and Dilafor as well as new share issues.
The CEO details unwound investment structures, adjusted stake values in Dilafor and Umecrine, notes positive clinical trial milestones, and welcomes a new board chair amid expanded equity.
STOCKHOLM, SWEDEN, October 30, 2026. KDventures AB (publ) (Nasdaq Stockholm: KDV) announces that its portfolio company Umecrine Cognition has reported topline results from the second...
The biotechnology company Modus Therapeutics, which is 51% owned by the investment firm KD Ventures, has temporarily paused recruitment for its phase-2a study with Sevuparin...
The life science investment company KD Ventures writes down the book value of its stake in Anacardio from SEK 60.6 million to around SEK 30.6 million, as per a...
KDventures AB ( ($SE:KDV.B) ) has shared an announcement. KDventures' portfolio company Umecrine Cognition has secured two Notices of Allowance from the U.S. Patent and...
Track KDventures and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to KDventures and other trending companies.
